Unclear from the article how this veto (or rather, the bill had it not been vetoed) interacts with the contact to produce insulin for the state of California.
It sort of sounds like that is still going ahead, but we all know insurers & pharmaceutical companies will use loopholes to avoid buying that CalRx insulin. Will that contract still be viable if the company is not supplying the bulk of diabetics in the state? Alternatively, will the contract render a cap unnecessary by virtue of undercutting for-profit insulin manufacturers?
Unclear from the article how this veto (or rather, the bill had it not been vetoed) interacts with the contact to produce insulin for the state of California.
It sort of sounds like that is still going ahead, but we all know insurers & pharmaceutical companies will use loopholes to avoid buying that CalRx insulin. Will that contract still be viable if the company is not supplying the bulk of diabetics in the state? Alternatively, will the contract render a cap unnecessary by virtue of undercutting for-profit insulin manufacturers?